Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The most common option of radiotherapy for patients with limited-stage DLBCL is
involved-field radiotherapy (IFRT). The more limited radiotherapy field size changing from
IFRT to reasonable margin from gross tumor has been reported to maintain the high rates of
local disease control, while minimizing the risks of radiation-induced toxicities. However,
the research didn't analyze whether the efficacy of consolidation involved-site radiotherapy
(ISRT) be affected by the response of chemotherapy. The biologic definition of clinical
target volume (CTV) of ISRT and actual radiotherapy field size need to be ascertained.